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Both Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are characterized by the deposition of hyperphosphorylated
forms of the microtubule-associated protein tau in neurons and/or glia. This unifying pathology led to the umbrella term
“tauopathies” for these conditions, also emphasizing the central role of tau in AD and FTD. Generation of transgenic mouse
models expressing human tau in the brain has contributed to the understanding of the pathomechanistic role of tau in disease.
To reveal the physiological functions of tau in vivo, several knockout mouse strains with deletion of the tau-encoding MAPT gene
have been established over the past decade, using diﬀerent gene targeting constructs. Surprisingly, when initially introduced tau
knockout mice presented with no overt phenotype or malformations. The number of publications using tau knockout mice has
recently markedly increased, and both behavioural changes and motor deﬁcits have been identiﬁed in aged mice of certain strains.
Moreover, tau knockout mice have been instrumental in identifying novel functions of tau, both in cultured neurons and in vivo.
Importantly, tau knockout mice have signiﬁcantly contributed to the understanding of the pathophysiological interplay between
Aβ and tau in AD. Here, we review the literature that involves tau knockout mice to summarize what we have learned so far from
depleting tau in vivo.
1.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia, characterized by a progressive decline of cognition
due to synaptic and neuronal loss [1]. Despite intensive
research into the cause of AD, there is no cure available to
date, and current treatment options are limited to symp-
tomatic relief [2]. This becomes even more alarming in the
light of over 35 million AD patients worldwide, a number
estimated to double by 2050 [3].
AD brains display two hallmark lesions upon autopsy:
amyloid β (Aβ)-containing plaques and neuroﬁbrillary tan-
gles (NFTs). Aβ results from β-a n dγ-secretase-mediated
proteolytic cleavage of the Aβ-precursor protein (APP) [4,
5] .N F T sa r em a d eu po fh y p e r p h o s p h o r y l a t e df o r m so f
the microtubule-associated protein tau [6]. In contrast to
AD, FTD presents with tau pathology in the absence of
an overt Aβ pathology. FTD is the second most prevalent
form of dementia occurring before the age of 65 [7–9].
FTD describes a heterogeneous group of neurodegenerative
disorders, including Pick’s disease (PiD), frontotemporal
dementia with Parkinsonism linked to chromosome 17
(FTDP-17), argyrophilic grain disease (AGD), corticobasal
degeneration (CBD), and progressive supranuclear palsy
(PSP). Sharing similar protein deposits, these disorders are
characterized by a broad spectrum of clinical symptoms
including behavioural changes, language abnormalities, and
motor dysfunction (reviewed in [7, 9]). While in familial
cases of AD (FAD), mutations were found in the APP- and
the presenilin genes 1 and 2 [10], the latter being part of the
γ-secretase complex [11], mutations in the MAPT gene were
found in familial FTD [12, 13].
The tau protein has been discovered in 1975 as a protein
with the ability to induce microtubule (MT) formation [14].
The tau-encoding gene MAPT is located on human chromo-
some 17q21 [15]. There are 6 tau isoforms, between 352 and
441 aminoacids in length, encoded by 11 exons in humans,
with alternative splicing of exons 2, 3, and 10 [16]. They
diﬀer by either the presence or absence of up to two amino-
terminal inserts (2N) and by containing either three (3R) or2 International Journal of Alzheimer’s Disease
four (4R) MT-binding repeats (MTB). While 3R isoforms
are predominant during embryonic brain development, the
normal adult brain has approximately equal levels of 3R and
4R isoforms [17]. Changes in this ratio have been linked to
the pathogenesis of tauopathies, with increased 4R levels in
ADandhighamountsof3RtauinPiD[18].Forcomparison,
mice and rats express only three diﬀerent 4R isoforms of tau,
but lack 3R tau [19].
Tau is expressed predominantly in neurons, where it is
enriched in axons. Tau is either bound to microtubules, the
inner side of the plasma membrane, or is unbound [20].
Besides stabilizing microtubules, tau has been implicated in
the regulation of motor-driven axonal transport [21, 22].
Other possible functions of tau include cellular signalling,
neuronal development, neuroprotection, and apoptosis [3,
23]. Furthermore, we have shown that tau is also present in
dendrites at low levels, where it is involved in postsynaptic
scaﬀolding [3, 24].
In AD and FTD, tau becomes increasingly phosphory-
lated at both physiological and pathological sites (referred
to as “hyperphosphorylated”) [25]. This aberrant phospho-
rylation detaches tau from microtubules, thereby probably
compromising its microtubule-stabilising functions (loss of
physiological function). At the same time, hyperphospho-
rylation of tau is the ﬁrst step in the formation of toxic
aggregates (gain of toxic function) and eventually of NFTs
[26]. Hyperphosphorylated tau accumulates in the soma of
neurons, giving rise to increased dendritic levels of tau [24,
27, 28]. However, there is good evidence that elevated levels
of soluble tau already contribute to neuronal dysfunction
prior to its deposition [29, 30], including for example,
disruption of axonal transport [31–34] and impairment of
mitochondrial function [35, 36].
The identiﬁcation of pathogenic mutations in AD and
FTD has led to the generation of multiple transgenic animal
models that recapitulate important aspects of the human
disease [37]. Transgenic mouse models, including those
with human tau expression, have become the major in vivo
tool in AD/FTD research (reviewed in [37]). In addition
to tau overexpressing mouse strains, several tau knockout
strains have been generated. Their contribution to the
understanding of tau is reviewed in this paper.
2. Tau Knockout Mice
Expression of tau in cell lines resulted in elongated process
formation, while tau reduction using antisense RNA sup-
p r e s s e da x o ne l o n g a t i o ni nc u l t u r e dn e u r o n s[ 38]. Based on
these ﬁndings in cells, tau depletion in mice was eagerly
awaited with expectations of marked eﬀects on neuronal
systems in vivo. Surprisingly, four independently generated
(conventional) tau knockout lines presented with no overt
phenotype [39–42]. Only when aged did tau knockout
mice develop behavioral impairments and motor deﬁcits
[43, 44].
In 1994, Harada and colleagues reported the ﬁrst tau
knockout mouse line (Figure 1(a)) [39] .T h em i c ea r ev i a b l e
and macroscopically normal. While immunohistochemical
analysis did not show changes, electron microscopical analy-
sis revealed decreased microtubule density in axons, together
with reduced cross-bridging between parallel microtubules,
and between microtubules and the plasma membrane.
Interestingly, neurons from this particular strain showed
normal axonal development in culture [39, 45]. The lack
of tau was associated with an up to 2 fold increase in the
microtubule-associated protein 1A (MAP1A) expression in
7-day-old,anda1.3foldincreaseinadulttauknockoutmice,
possibly compensating for the absence of tau [39]. Although
M A P 1 Bl e v e l sw e r er e p o r t e d l yn o r m a li nt h i st a uk n o c k o u t
line, cross-breeding of tau with MAP1B knockout mice
exacerbated hypoplastic axon tracts, disorganized neuronal
layering, and impaired maturation of primary neurons of
MAP1B mice [45].
In 2001, two additional tau knockout lines have been
published. Tucker and colleagues generated tau knockout
mice by integrating GFP-encoding cDNA into exon 1 of
MAPT, resulting in expression of a GFP fusion protein
with aminoacids 1 to 31 of tau, together with deletion of
endogenous tau expression (Figure 1(b)) [41]. While the
original report did use heterozygote tau knockout mice to
image GFP expressing neurons, as well as sorting neurons
for in vitro analysis, tau function has not been studied.
Nevertheless, this particular strain has been used in several
subsequentstudiestoidentifynovelfunctionsoftau[24,46].
Dawson and colleagues generated tau knockout mice
by homologous recombination replacing exon 1 with a
neomycin expression cassette (Figure 1(c)) [40]. Again, these
mice are viable and display no overt anomalies. Similar
to previous tau knockout mice [39] ,M A P 1 Al e v e l sw e r e
approximately 2-fold increased at birth, but declined with
brain maturation. In fact, MAP1A levels were similar in
wildtype and tau knockout mice at 12 months of age [40].
Hence, MAP1A may compensate for loss of tau during early
b r a i nd e v e l o p m e n t ,b u tn o ti nt h em a t u r eb r a i n[ 39, 40, 42].
Contrary to previous studies, primary neurons obtained
from this tau knockout strain showed slowed maturation
with reduced neurite length throughout all developmental
stages and reduced axon length of stage 3 neurons [40].
The most recent tau knockout mouse has been estab-
lished by Fujio and colleagues in 2007 [42]. They intro-
duced a neomycin cassette in reverse orientation ﬂanked by
ﬂippase recognition targets (FRTs) into exon 1 of MAPT
(Figure 1(d)). Similar to previous tau knockout mice, they
are viable and show no overt anomalies. MAP1A levels were
increased as previously reported for other tau knockout
strains [40].
Taken together, in three of four independent tau knock-
out strains, MAP1A is increased around birth but not in
adult brain (NB: MAP1A levels have not been determined in
thefourthstrain),suggestingearlybutnotlatecompensation
for loss of tau by MAP1A [39, 40, 42]. On the other
hand, neuronal maturation has been examined in two of
four tau knockout lines, with diﬀerent results [39, 40, 47].
Here, analysis of additional lines may provide clariﬁcation.
Diﬀerences between the diﬀerent tau knockout strains may
be explained by diﬀerent genetic backgrounds used.International Journal of Alzheimer’s Disease 3
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Figure 1: Homologous recombination strategies for the generation of diﬀerent tau knockout mice reported by (a) Harada and collegues
[39], (b) Tucker and colleagues [41], (c) Dawson and colleagues [40], and (d) Fujio and colleagues [42].
3. Deﬁcits in Tau Knockout Mice
Neuronal dysfunction and neurodegeneration in tauopathies
is due to the toxicity of pathologically modiﬁed tau and/or
loss of physiological tau function [48]. While the reported
tau knockout strains presented without overt phenotype
when young [39–42], one-year-old mice of one tau knock-
out strain [39] showed muscle weakness in the wire-
hanging test, reduced balancing in the rod-walking test,
hyperactivity in new environments and impaired contextual
fear conditioning [43]. Interestingly, muscle weakness was
already detectable in heterozygote tau knockout mice. The
spatial learning ability of this tau knockout strain, however,
presented normal, when tested in the eight-arm radial maze
and the Morris water maze [43]. Normal performance by 7-
and 12-month-old tau knockout mice in the Morris water
maze has since been independently conﬁrmed in another
strain [49, 50]. The latter strain also performed normal in
the radial water arm maze and on the Rotarod at 12 months
of age [50]. However, Lei and colleagues recently identiﬁed
morecomplexmotordeﬁcitsinthesametauknockoutstrain
at 12 months of age, with increased turn time in the pole
test, reduced performance on the Rotarod and decreased
locomotion in the open ﬁeld test [44]. These deﬁcits were
associated with reduced numbers of tyrosine hydroxylase-
positive substantia nigra (SN) neurons [44]. Interestingly,
mutanttauoverexpressionalsoresultsinalossofSNneurons
inamousemodelofFTDwithParkinsonism[33],suggesting
that tau levels are critical for this neuronal population;
however, the exact role of tau herein remains unknown.
Taken together, tau knockout mice appear to develop motor
deﬁcits with increasing age, suggesting that loss of physi-
ological tau function may contribute to the motor deﬁcits
observed in tauopathy patients. Further, tau knockout mice
show no overt memory deﬁcits in spatial memory tasks,
which is consistent with sole tau pathology in humans, such
as in FTD, where memory function is not or only mildly
compromised.
Cantero and colleagues examined the local ﬁeld potential
from various cortical regions and hippocampus of tau
knockout mice to determine if delayed axonal maturation of
tau knockout neurons observed in vitro [40] could possibly4 International Journal of Alzheimer’s Disease
aﬀect neuronal circuit formation in vivo [51]. They found
slower theta rhythms of the hippocampus and reduced
gamma synchronization between cortical brain regions in
tau knockout mice, which may suggest impaired circuit
formation. To this end, the morphological correlates of these
ﬁndings remain unknown, but dysfunctional neuronal net-
works have been implicated in the pathogenesis of AD
[52]. Furthermore, tau knockout mice have abnormal sleep-
wake cycle, with increased wakefulness periods and reduced
nonrapid eye movements [53]. Taken together, tau may play
a role in neuronal circuit formation.
4. Tau Knockout Mice withHuman
Tau Expression
Overexpression of human tau derived from a human P1-
derived artiﬁcial chromosome (PAC) in mice results in
expressionofall6humantauisoformsinmousebrainsinthe
absence of any neuropathology [54]. Interestingly, crossing
of PAC tau transgenic mice with tau knockout mice results
in accumulation of hyperphosphorylated tau and formation
of sarkosyl-insoluble 3R, but not 4R tau as early as 2 months
of age [46]. Furthermore, 12-month-old PAC tau transgenic
mice on a tau knockout background present with memory
deﬁcits in the Morris water maze task and perturbed LTP
formation [55]. These aged mice are further characterized
by neuronal loss together with ventricle enlargement and
reducedcorticalthickness[56].Similarly,depletionofmouse
tau exacerbated tau pathology in transgenic mice expressing
double mutant human tau [57]. Together, this suggests that
endogenous mouse tau prevents pathological alteration of
transgenic human tau. The underlying mechanisms remain,
however, elusive.
Sennvik and colleagues generated knockin mice by
inserting cDNA that encodes the longest human tau isoform
(2N4R) into exon 1 of the MAPT gene [58]. Surprisingly,
neuronal numbers were increased in the hippocampus of
thesemice,asaresultofincreasedneurogenesisandneuronal
survival during development. This is accompanied by an
improved performance in the novel object recognition task.
Similar to other tau-deﬁcient strains [40], maturation of
primary neurons is delayed in primary cultures from these
human tau knockin mice, probably because expression of
human tau is only detectable after 10 days in vitro (DIV).
Interestingly, at 4 DIV, human tau knockin neurons show
proliferative markers, which disappear at the onset of human
tau expression at 10 DIV and neuronal maturation [58].
Although mechanistically unclear, this may suggest anti-
proliferative and prodiﬀerentiation eﬀects of human 2N4R
tau.
5. GeneandProteinRegulation inTau
Knockout Mice
Tau depletion is associated with a 2 fold increase in MAP1A
levelsin newborn mice,buttheyarereducedtonormal levels
thereafter [39, 40]. This possible early compensation of the
loss of tau by MAP1A has been reported together with the
ﬁrst tau knockout mice [39]. Since then, tau knockout mice
have been subjected to both educated guess approaches and
unbiased screening methods to identify additional genes and
proteinsthatarederegulated,tofurtherunderstandtau’srole
in vivo.
Tauhasbeenshowntointeractwithhistonedeacetylase6
(HDAC6),atubulindeacetylase,viathemicrotubulebinding
domainoftauandtheSE14domainofHDAC6thatmediates
its enzymatic activity [59]. Perez and colleagues showed that
tau, in particular aggregated tau, inhibits HDAC6 activity in
vitro, together with reduced levels of acetylated tubulin in
primary tau knockout neurons, suggesting that tau regulates
HDAC6 activity [60]. Another class of proteins that forms
complexes with tau is 14-3-3, a group of scaﬀolding proteins
[61–63]. However, the absence of changes in levels and
interaction with microtubules of diﬀerent 14-3-3 isoforms
in tau knockout mice suggest that the interaction between
tau and 14-3-3 is rather only relevant under conditions
with increased levels of unbound tau [42], given that the
interaction involves the microtubule-binding domain of tau
that is normally preoccupied with tubulin [61].
Unbiased gene expression analysis revealed several genes
that are changed in tau knockout compared to wildtype
mouse brains [47, 64]. Oyama and colleagues identiﬁed
severalmRNAs that are deregulatedin brains of tau-deﬁcient
mice [64]. Of those, Gem GTPase, a regulator of Rho
signaling and inducer of cellular process formation, was
signiﬁcantly increased in tau knockout brains. In cells, tau
suppressed the activity of Gem GTPase via its microtubule-
binding domain, suggesting that tau may be involved in reg-
ulating Gem GTPase downstream signaling [64]. In another
mRNA screening, de Barreda and colleagues found increased
BAF57 mRNA and protein levels in the hippocampus of tau
knockout mice [47]. BAF57 interacts with coREST, which
in turn activates the transcriptional repressor REST and
consequently the expression of neuronal speciﬁc genes [65].
Here, tau may act as a nuclear regulator of gene expression.
Accordingly, tau can be isolated from nuclei of hippocampal
cells [47, 66].
Taken together, analysis of deregulated genes and pro-
teins in tau knockout mice proves valuable for the identiﬁ-
cation of novel tau functions. Advanced screening methods,
such as next-generation sequencing, may provide further
insights into tau-dependent processes in the future.
6. Protection from Aβ Pathology
According to the amyloid cascade theory, Aβ is upstream
of tau pathology in the pathogenesis of AD [67]. This has
been reproduced in mutant tau transgenic mouse models
withNFTformation,bycrossingthemwithAβ-formingAPP
transgenic mice [68], or injecting Aβ into their brains [69],
both resulting in increased NFT pathology. Interestingly, in
2002, Rapoport and colleagues provided the ﬁrst evidence
that tau is also needed for Aβ to cause its toxicity in neurons
in vitro, as suggested by resistance of primary cultured
neurons from tau knockout mice to Aβ exposure [70]. It
was not until 2007, when Roberson and colleagues repro-
duced this ﬁnding in vivo, by crossing Aβ-forming APPInternational Journal of Alzheimer’s Disease 5
transgenic mice, which display premature mortality and
memory deﬁcits, on a tau knockout background [49]. Both
hetero- and homo-zygote tau deﬁciency rescued premature
mortality and prevented memory deﬁcits in APP trans-
genic mice. Mechanistically, this protection appeared to be
conferred by reduced susceptibility to excitotoxicity in tau
knockout mice [49]. Excitotoxicity describes a signalling
cascadethatisinducedbyoveractivationofNMDAreceptors
(NMDARs) that results in neuronal damage and death, and
excitotoxicity has been implicated as a pathomechanism
underlying neurodegeneration induced by Aβ in AD [71].
We reproduced the protection from Aβ-induced premature
mortality and memory deﬁcits, using independent APP
transgenic, and tau knockout mice, also showing that
reduced susceptibility to excitotoxicity of the latter underlies
this protection [24]. Furthermore, we used expression of
a dominant-negative truncation mutant of tau to prevent
deﬁcitsinAPPtransgenicmice.Togetherwiththetauknock-
out mice, we were able to show for the ﬁrst time that tau
is critically involved in postsynaptic NMDAR downstream
signalling, by localizing the Src kinase Fyn to dendrites,
where it mediates coupling of NMDAR complexes to postsy-
naptic scaﬀolding proteins and therefore signalling cascades.
ReducedpostsynapticFynlevelsintau-deﬁcientortruncated
tau expressing mice results in uncoupling of NMDARs from
excitotoxic downstream signalling and therefore prevention
of Aβ mediated toxicity [3, 24]. Hence, Aβ, Fyn and tau
may orchestrate neuronal damage in AD mouse models [24,
72, 73], suggesting a critical role of tau in the pathogenesis
of AD [3]. This data is consistent with previous reports
on the preventive eﬀects of Fyn depletion and accelerating
eﬀects of Fyn expression on the deﬁcits in APP transgenic
mice [74, 75]. Further, supporting the protective eﬀects of
tau depletion, Shipton and colleagues showed recently that
Aβ-mediated impairment of LTP in hippocampal slices of
wildtype mice is prevented in tau knockout mice [76]. LTP
formation per se was normal in tau knockout mice [76],
consistent with normal excitatory postsynaptic potential
(EPSP) recordings in two diﬀerent tau knockout strains
[24, 73]. To this end, while several studies showed protection
from Aβ toxicity by knocking out tau [24, 49, 70, 77], one
other study showed increased pathology in aged mice [50],
possibly reﬂecting diﬀerent eﬀects based on the usage of
diﬀerent APP transgenic lines.
The exact downstream mechanisms involved in medi-
ating protection from Aβ toxicity in tau knockout mice
remains to be shown. These may include axonal transport,
which is known to be regulated by tau [22]. While basal
axonal transport rates are unaﬀected in tau knockout neu-
rons [77, 78], impairment of axonal transport of mitochon-
driaandTrkA-containingvesiclesinducedbyAβ isprevented
in tau-deﬁcient neurons [77]. Furthermore, increased Aβ-
formation is associated with increased activity of GSK3β,
a known tau kinase [79, 80]. GSK3β overexpression in
the brain of mice results in degeneration of the dentate
gyrus, but this is signiﬁcantly ameliorated when crossed
with tau-deﬁcient mice [81]. Tau knockout neurons also
show increased resistance to heat shock [82]. While Hsp70
levels were increased upon heat shock in both wildtype and
tau knockout neurons, Akt phosphorylation was delayed
togetherwithavirtualabsenceofGSK3βactivation.Whether
Akt/GSK3βsignallingplaysaroleinpreventingAβtoxicityin
tau knockout mice remains to be shown. If other tau kinases
or phosphatases are involved also remains to be shown.
Furthermore, protection of tau knockout neurons may be
conferred by nuclear tau [83].
The protection from Aβ toxicity in tau knockout mice
seems to be rather speciﬁc, since it does not prevent deﬁcits
in models of several other neurodegenerative disorders.
Accordingly, crossing of mutant SOD1 expressing mice, a
model of amyotrophic lateral sclerosis (ALS), on a tau
knockout background, does not prevent weight loss and
death [73]. Furthermore, motor deﬁcits of mouse models of
Parkinson’s disease (PD) are not prevented on a tau-deﬁcient
background [84] .Th eP Dm od el su s edw e r es tri a t a li n j ecti o n
of 6-hydroxydopamine and transgenic expression of α-
synuclein, neither of which showed improvement. Similarly,
tau depletion does not protect from deﬁcits induced by
intracranial administration of prions [84]. Tau depletion is
associated with silver positive spheroids in yet another APP
transgenic mouse strain when aged [50]. Finally, knocking
out tau even exacerbated the phenotype of NPC deﬁcient
mice, a model of Niemann-Pick disease type C, suggesting
a role of tau in regulation of autophagy [85].
Takentogether,taureductionpreventsmicefromspeciﬁc
Aβ-mediated deﬁcits, supporting a central role of tau in
mediating Aβ toxicity in the early pathogenesis of AD.
However, tau depletion does not generally prevent from neu-
rodegenerative conditions, suggesting distinct mechanisms.
7. Concluding Remarks
Tothisend,tauknockoutmicehavesigniﬁcantlycontributed
tounravelingnovelfunctionsoftauunderphysiologicalcon-
dition and its role in disease. While key ﬁndings have been
reproducedinindependenttau-deﬁcientstrains,others,such
asdelayedaxonalmaturation[40],remaintobeconﬁrmedin
alternative strains. Diﬀerences may also be due to the usage
of diﬀerent genetic backgrounds with possible confounding
eﬀects. Understanding the diﬀerences might contribute to a
broader knowledge about the physiologic function of tau,
which may be translated to understanding the mechanisms
of tauopathies.
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